Education & Training

 

AGA Education, Practice and Research

Focused Clincial Updates 2006

To receive full CME credit, you are required to complete the evaluation form and self-test for each chapter you complete. Upon completion of the evaluation form and test, a certificate with your name and number of credits you have claimed will be generated. You must print your certificate using the print function in your browser.

The objectives listed below are to be used when evaluating the program. After completing this program, each participant should be able to:

  • Identify how state of the art and emerging research will impact management of digestive conditions.
  • Review diagnostic and treatment options for patients with several digestive diseases.

 

GI Bleeding

Select one answer for each question. You may change your answers as many times as you need to until you click the "Submit" button located at the bottom of the test.

1. Early re-introduction of low dose aspirin following an acute peptic ulcer bleed results in which of the following?

An increase in rebleeding compared to placebo when both groups are on IV PPI

A decrease in one and two month mortality compared to placebo

No difference in bleeding rates compared to placebo at 30 days

B and C are correct

2. Which of the following is correct comparing second look endoscopy to intravenous PPI in high-risk GI bleeding after endoscopic hemostasis?

Second look endoscopy is superior to IV PPI in preventing rebleeding

Second look endoscopy resulted in no difference in the number of patients requiring surgery

Intravenous PPI significantly decreased recurrent bleeding and need for surgery

None of the above

3. Intravenous proton pump inhibitor initiated prior to endoscopic diagnosis in upper GI bleeding:

Resulted in a decrease in mortality, rebleeding and the need for surgery

Increased the chance of finding stigmata of recent hemorrhage

Had no effect on mortality, rebleeding, or need for surgery

All are correct

4. In comparing esomeprazole 20 mg twice daily plus celecoxib 200 mg twice daily to celecoxib plus placebo in patients with NSAID-induced ulcer bleeding:

There was no difference in rebleeding rates between the groups

Celecoxib alone was superior to celecoxib plus esomeprazole

Esomeprazole plus celecoxib was superior to coxib alone

None of the above